ZN-c3

selective oral Wee1 kinase inh. (300 mg QD)

Ph. II candidate for uterine serous carcinoma

from literature starting point

Journal of Medicinal Chemistry

Zentalis Pharmaceuticals, San Diego, CA, USA

The Zentalis Wee1 inhibitor, ZN-c3, is a highly selective kinase inhibitor that is currently being evaluated in Ph. II clinical trials in adult women with recurrent or persistent uterine serous…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks